NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2005
Business Overview: NAI provides private label contract manufacturing services for vitamins, minerals, herbs, and nutritional supplements. It also operates a direct-to-consumer marketing program. The company operates manufacturing facilities in Vista, California, and Manno, Switzerland (via subsidiary NAIE). NAI achieved record net sales in fiscal 2005, driven primarily by growth in its two largest customers.

Key Financial Metrics

Revenue Mix: Private label contract manufacturing accounted for $83.4 million (91% of sales), while direct-to-consumer sales were $8.1 million (9%).
Customer Concentration: The two largest customers, NSA International, Inc. (40%) and Mannatech, Incorporated (39%), comprised 79% of total net sales.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 16% year-over-year, driven by a 22% increase in private label sales. Growth was attributed to higher volumes from NSA International and Mannatech, partially offset by the discontinuation of two customer relationships due to risk concerns.
• Margin Compression: Gross margin declined to 20.1% from 23.6%. This was primarily caused by a shift in sales mix toward lower-margin powder products (31% of sales vs. 20% prior year) and increased overhead costs related to facility expansion and regulatory compliance.
• Profitability Decline: Despite higher operating income, net income fell 27% to $2.2 million. This was largely due to a significant increase in the effective tax rate from 1% in 2004 to 35.5% in 2005, following the expiration of a Swiss tax holiday and the reversal of a valuation allowance on deferred tax assets in the prior year.
• Capital Expenditures: Capital spending surged to $7.7 million (up from $3.3 million) to fund the expansion of the Vista, California facility and acquisition of manufacturing equipment.

Guidance, Outlook, and Risks

Outlook: Management expects to continue the trend of annual revenue growth and long-term operating income growth. However, they anticipate quarterly fluctuations due to customer order timing and new product introductions. The company plans to leverage its new facility and TGA recertification to attract quality-oriented customers and expand branded product initiatives.

Key Risks and Contingencies:

• Customer Concentration: Heavy reliance on two customers (79% of sales) creates significant risk; a loss of either would materially impact operations.
• Regulatory Compliance: The company faces extensive regulation by the FDA and international bodies. Increased compliance costs (e.g., TGA certification) impacted margins.
• Legal Proceedings: A patent infringement lawsuit was filed by Novogen Research Pty. Ltd. in February 2005. The company intends to defend the action vigorously.
• Supplier Dependency: Carrington Laboratories Inc. accounted for 35% of raw material purchases.
• Foreign Currency: Operations in Switzerland and sales in Euros expose the company to exchange rate fluctuations. A 10% adverse change in rates could decrease net income by approximately $762,000.

Investor Verification Checklist

• Customer Retention: Verify the stability of relationships with NSA International and Mannatech, which drive nearly 80% of revenue.
• Margin Recovery: Assess whether the shift to powder products is a permanent trend or if the company can improve mix to restore gross margins.
• Tax Rate Normalization: Confirm the sustainability of the 35.5% effective tax rate now that the Swiss tax holiday has expired.
• Liquidity Position: Review the impact of the $7.7 million capital expenditure on cash reserves ($1.9 million) and the utilization of the $12 million credit facility.
• Legal Exposure: Monitor the status of the Novogen patent infringement litigation for potential settlement costs or injunctions.